Literature DB >> 19171138

Functional imaging in Huntington's disease.

Jane S Paulsen1.   

Abstract

Huntington's disease (HD) is a genetic brain disease characterized by loss of capacity in movement control, cognition, and emotional regulation over a period of about 30 years. Since it is well established that clinical impairments and brain atrophy can be detected decades prior to receiving a clinical diagnosis, functional neuroimaging efforts have gained momentum in HD research. In most brain disorders, there is accumulating evidence that the clinical manifestations of disease do not simply depend on the extent of tissue loss, but represent a complex balance among neuronal dysfunction, tissue repair, and circuitry reorganization. Based upon this premise, functional neuroimaging modalities may be more sensitive to the earliest changes in HD than are structural imaging approaches. For this review, PET and fMRI studies conducted in HD samples were summarized. Strengths and limitations of the utilization of functional imaging in HD are discussed and recommendations are offered to facilitate future research endeavors.

Entities:  

Mesh:

Year:  2009        PMID: 19171138      PMCID: PMC3810959          DOI: 10.1016/j.expneurol.2008.12.015

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  86 in total

Review 1.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

Authors:  G E Alexander; M R DeLong; P L Strick
Journal:  Annu Rev Neurosci       Date:  1986       Impact factor: 12.449

2.  Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.

Authors:  D E Kuhl; C H Markham; E J Metter; W H Riege; M E Phelps; J C Mazziotta
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1985

3.  Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone.

Authors:  J Hägglund; S M Aquilonius; S A Eckernäs; P Hartvig; H Lundquist; P Gullberg; B Långström
Journal:  Acta Neurol Scand       Date:  1987-02       Impact factor: 3.209

4.  Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.

Authors:  D E Kuhl; E J Metter; W H Riege; C H Markham
Journal:  Ann Neurol       Date:  1984       Impact factor: 10.422

5.  Computed tomographic, neurologic, and neuropsychological correlates of Huntington's disease.

Authors:  D S Sax; B O'Donnell; N Butters; L Menzer; K Montgomery; H L Kayne
Journal:  Int J Neurosci       Date:  1983       Impact factor: 2.292

6.  Normal caudate glucose metabolism in persons at risk for Huntington's disease.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D Markel; S Berent; J Rothley; A Betley; R Hichwa
Journal:  Arch Neurol       Date:  1987-03

7.  Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.

Authors:  D E Kuhl; M E Phelps; C H Markham; E J Metter; W H Riege; J Winter
Journal:  Ann Neurol       Date:  1982-11       Impact factor: 10.422

8.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.

Authors:  J C Mazziotta; M E Phelps; J J Pahl; S C Huang; L R Baxter; W H Riege; J M Hoffman; D E Kuhl; A B Lanto; J A Wapenski
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

9.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

10.  Positron emission tomography in the early diagnosis of Huntington's disease.

Authors:  M R Hayden; W R Martin; A J Stoessl; C Clark; S Hollenberg; M J Adam; W Ammann; R Harrop; J Rogers; T Ruth
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

View more
  37 in total

Review 1.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

3.  Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease.

Authors:  Robert C Wolf; Georg Grön; Fabio Sambataro; Nenad Vasic; Nadine D Wolf; Philipp A Thomann; Carsten Saft; G Bernhard Landwehrmeyer; Michael Orth
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-11       Impact factor: 6.200

4.  Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease.

Authors:  Paul G Unschuld; Suresh E Joel; Xinyang Liu; Megan Shanahan; Russell L Margolis; Kevin M Biglan; Susan S Bassett; David J Schretlen; Graham W Redgrave; Peter C M van Zijl; James J Pekar; Christopher A Ross
Journal:  Neurosci Lett       Date:  2012-03-07       Impact factor: 3.046

5.  Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex.

Authors:  Paul G Unschuld; Suresh E Joel; James J Pekar; Sarah A Reading; Kenichi Oishi; Julie McEntee; Megan Shanahan; Arnold Bakker; Russell L Margolis; Susan S Bassett; Adam Rosenblatt; Susumu Mori; Peter C van Zijl; Christopher A Ross; Graham W Redgrave
Journal:  Psychiatry Res       Date:  2012-09-11       Impact factor: 3.222

6.  Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease.

Authors:  Meike Herben-Dekker; Joost C H van Oostrom; Raymund A C Roos; Caroline K Jurgens; Marie-Noëlle W Witjes-Ané; Hubertus P H Kremer; Klaus L Leenders; Jacoba M Spikman
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

7.  Frontal cortex BOLD signal changes in premanifest Huntington disease: a possible fMRI biomarker.

Authors:  Stefania Ferraro; Lorenzo Nanetti; Sylvie Piacentini; Maria L Mandelli; Nicola Bertolino; Francesco Ghielmetti; Francesca Epifani; Anna Nigri; Franco Taroni; Maria G Bruzzone; Stefano Di Donato; Mario Savoiardo; Caterina Mariotti; Marina Grisoli
Journal:  Neurology       Date:  2014-06-04       Impact factor: 9.910

8.  Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.

Authors:  Nicole M Lewandowski; Yvette Bordelon; Adam M Brickman; Sergio Angulo; Usman Khan; Jordan Muraskin; Erica Y Griffith; Paula Wasserman; Liliana Menalled; Jean Paul Vonsattel; Karen Marder; Scott A Small; Herman Moreno
Journal:  Neurobiol Dis       Date:  2012-12-04       Impact factor: 5.996

9.  Neural correlates of impaired emotion processing in manifest Huntington's disease.

Authors:  Imis Dogan; Christian Saß; Shahram Mirzazade; Alexandra Kleiman; Cornelius J Werner; Anna Pohl; Johannes Schiefer; Ferdinand Binkofski; Jörg B Schulz; N Jon Shah; Kathrin Reetz
Journal:  Soc Cogn Affect Neurosci       Date:  2013-03-11       Impact factor: 3.436

10.  Striatal hypometabolism in premanifest and manifest Huntington's disease patients.

Authors:  Diego Alfonso López-Mora; Valle Camacho; Jesús Pérez-Pérez; Saül Martínez-Horta; Alejandro Fernández; Frederic Sampedro; Alberto Montes; Gloria Andrea Lozano-Martínez; Beatriz Gómez-Anson; Jaime Kulisevsky; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.